|
1
|
Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society.
|
Radiology
|
2005
|
9.83
|
|
2
|
The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer.
|
J Thorac Oncol
|
2007
|
2.93
|
|
3
|
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003.
|
J Clin Oncol
|
2012
|
2.72
|
|
4
|
Changes in the use and costs of diagnostic imaging among Medicare beneficiaries with cancer, 1999-2006.
|
JAMA
|
2010
|
2.68
|
|
5
|
Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
|
J Thorac Oncol
|
2008
|
2.67
|
|
6
|
Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.
|
Cancer
|
2009
|
2.06
|
|
7
|
FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
|
J Thorac Oncol
|
2015
|
2.02
|
|
8
|
Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.
|
Cancer
|
2006
|
1.91
|
|
9
|
National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population.
|
Ann Intern Med
|
2014
|
1.56
|
|
10
|
Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma.
|
J Clin Oncol
|
2008
|
1.38
|
|
11
|
Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer.
|
Cancer Res
|
2003
|
1.34
|
|
12
|
Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007.
|
Radiology
|
2013
|
1.30
|
|
13
|
Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis.
|
Proteomics
|
2003
|
1.27
|
|
14
|
Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project.
|
J Natl Cancer Inst
|
2006
|
1.24
|
|
15
|
Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma.
|
Cancer
|
2004
|
1.16
|
|
16
|
Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer.
|
Cancer
|
2007
|
1.11
|
|
17
|
Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer.
|
Lung Cancer
|
2004
|
1.10
|
|
18
|
National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.
|
J Thorac Oncol
|
2010
|
1.04
|
|
19
|
Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
|
Cancer Res
|
2005
|
1.03
|
|
20
|
Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer.
|
Lung Cancer
|
2004
|
1.01
|
|
21
|
False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications.
|
AJR Am J Roentgenol
|
2004
|
1.00
|
|
22
|
PET imaging in patients with bronchioloalveolar cell carcinoma.
|
Lung Cancer
|
2002
|
0.97
|
|
23
|
Characterising phase variations in MALDI-TOF data and correcting them by peak alignment.
|
Cancer Inform
|
2005
|
0.95
|
|
24
|
T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET.
|
Radiology
|
2002
|
0.95
|
|
25
|
The role of imaging in malignant pleural mesothelioma.
|
Semin Oncol
|
2002
|
0.93
|
|
26
|
Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate.
|
Anal Chem
|
2004
|
0.91
|
|
27
|
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment.
|
J Thorac Oncol
|
2006
|
0.91
|
|
28
|
Practical approach to diagnostic CT combined with PET.
|
AJR Am J Roentgenol
|
2007
|
0.89
|
|
29
|
Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer.
|
Cancer
|
2010
|
0.88
|
|
30
|
Analysis of human serum proteins by liquid phase isoelectric focusing and matrix-assisted laser desorption/ionization-mass spectrometry.
|
Proteomics
|
2003
|
0.86
|
|
31
|
Complement factor H autoantibodies are associated with early stage NSCLC.
|
Clin Cancer Res
|
2010
|
0.84
|
|
32
|
Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005.
|
J Thorac Oncol
|
2014
|
0.84
|
|
33
|
Throughput and efficiency of a mass spectrometry-based screening assay for protein-ligand binding detection.
|
J Am Soc Mass Spectrom
|
2008
|
0.81
|
|
34
|
Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence.
|
J Thorac Oncol
|
2007
|
0.81
|
|
35
|
Finding diagnostic biomarkers in proteomic spectra.
|
Pac Symp Biocomput
|
2006
|
0.80
|
|
36
|
The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer.
|
J Thorac Oncol
|
2011
|
0.79
|
|
37
|
Isolation of novel EGFR-specific VHH domains.
|
J Biomol Screen
|
2009
|
0.78
|
|
38
|
Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303).
|
Cancer
|
2011
|
0.78
|
|
39
|
Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival?
|
J Clin Oncol
|
2008
|
0.77
|
|
40
|
Discovery of novel cyclophilin A ligands using an H/D exchange- and mass spectrometry-based strategy.
|
J Biomol Screen
|
2010
|
0.76
|
|
41
|
Reply to M.S. Hofman et al.
|
J Clin Oncol
|
2013
|
0.75
|
|
42
|
Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography".
|
J Thorac Oncol
|
2015
|
0.75
|
|
43
|
Preliminary evaluation of biplane correlation (BCI) stereographic imaging for lung nodule detection.
|
J Digit Imaging
|
2013
|
0.75
|
|
44
|
Hydrogen/deuterium exchange- and protease digestion-based screening assay for protein-ligand binding detection.
|
Anal Chem
|
2009
|
0.75
|
|
45
|
Future trends in lung cancer diagnosis.
|
Radiol Clin North Am
|
2012
|
0.75
|
|
46
|
Development of novel tumor imaging agents with phage-display combinatorial peptide libraries.
|
Acad Radiol
|
2002
|
0.75
|
|
47
|
Accentuation of differentially expressed proteins using phage technology.
|
Anal Biochem
|
2004
|
0.75
|
|
48
|
Thoracic imaging.
|
Respirology
|
2010
|
0.75
|